Given that EZH2 is overexpressed in MM and of prime importance in multiple oncogenic pathways promoting MM cell growth, survival and resistance to currently used treatments, supports its evaluation for use in targeted therapy in MM. Here, EZH2 is linked to Miyoshi myopathy.